Search clinical trials for: RPC1063

Total 23 results

Celgene

Completed

A Study to Evaluate the Relative Bioavailability of a Pediatric Granule Formulation of Ozanimod in Healthy Adult Subjects

Healthy Volunteers

United States
Celgene

Completed

Efficacy and Safety Trial of RPC1063 for Moderate to Severe Crohn's Disease

Crohn's Disease

United States, Poland, Ukraine, Hungary, Canada
Celgene

Completed

A Single Dose Oral Excretion Balance Study of [14C]-RPC1063 in Healthy Male Adults

Healthy Volunteers

United Kingdom
Celgene

Completed

Safety and Efficacy Trial of RPC1063 for Moderate to Severe Ulcerative Colitis

Ulcerative Colitis

Korea, Republic of, United States, Belgium, Israel, Netherlands, Australia, Germany, Hungary, New Zealand, Italy, Canada, Bulgaria, Croatia, United Kingdom, Argentina, Austria, Belarus, Czechia, Georgia, Moldova, Republic of, Po... and more
Bristol-Myers Squibb

Recruiting

A Study Investigating Oral Ozanimod (RPC1063) in Pediatric Participants With Moderate to Severe Active Ulcerative Colitis

Colitis, Ulcerative

United States, Belgium, Germany, Japan, France, Russian Federation, Spain, Poland, Australia, Canada, Israel, United Kingdom
Bristol-Myers Squibb

Recruiting

A Study to Evaluate the Efficacy, Safety, and Drug Levels of Oral Ozanimod in Pediatric Participants With Moderately to Severely Active Crohn's Disease With an Inadequate Response to Conventional Therapy

Crohn Disease

United States, Belgium, Hungary, France, Canada, Spain, Australia, Germany, Poland, United Kingdom
Celgene

Active, not recruiting

An Extension Study of RPC1063 as Therapy for Moderate to Severe Ulcerative Colitis

Ulcerative Colitis

United States, Germany, Greece, United Kingdom, Hungary, Belgium, Slovakia, Bulgaria, Italy, Australia, Israel, Belarus, Romania, Ukraine
Celgene

Completed

A Study to Evaluate Safety and Effectiveness of Cendakimab (CC-93538) in Participants With Moderate to Severe Atopic Dermatitis

Eczema | Dermatitis, Atopic

United States, Canada, Japan, Poland, China, Czechia
Celgene

Completed

Pharmacokinetics and Pharmacodynamics Study of RPC1063 in RMS

Multiple Sclerosis

United States
Celgene

Completed

Efficacy and Safety Study of Ozanimod (RPC1063) in Relapsing Multiple Sclerosis Patients (RADIANCE)

Relapsing Multiple Sclerosis

Serbia, United States, Poland, Spain, Belgium, Bulgaria, Georgia, Greece, Romania, Russian Federation, Ukraine, Hungary, Italy
University Hospital, Angers

Unknown

Multicentric Trial of the Treatment of Huntington's Disease by Cysteamine (RP103)

Huntington's Disease

France
Celgene

Completed

A Multi-Site, Open-Label Extension Trial of Oral RPC1063 in Relapsing Multiple Sclerosis

Multiple Sclerosis

United States, Belarus, Belgium, Bosnia and Herzegovina, Bulgaria, Croatia, Estonia, Georgia, Germany, Greece, Hungary, Italy, Latvia, Lithuania, Moldova, Republic of, New Zealand, Poland, Portugal, Romania, Serbia, Slovakia, South... and more
Horizon Pharma USA, Inc.

Completed

Open-Label, Dose-Escalating Study Assessing Safety, Tolerability, Efficacy, of RP103 in Mitochondrial Disease (MITO-001)

Inherited Mitochondrial Disease, Including Leigh Syndrome

United States
Horizon Pharma USA, Inc.

Completed

Pilot Study of Safety, Tolerability, Pharmacokinetics/Pharmacodynamics of RP103 Compared to Cystagon® in Patients With Cystinosis

Cystinosis

United States
Celgene

Completed

Efficacy and Safety Study of Ozanimod in Relapsing Multiple Sclerosis (RADIANCE)

Relapsing Multiple Sclerosis

Spain, United States, United Kingdom, Croatia, Serbia, Belarus, Hungary, Bulgaria, Poland, Italy, Ukraine, Greece, Belgium, Georgia, Bosnia and Herzegovina, Moldova, Republic of, Romania, Russian Federation, Slovakia, South Africa and more
Horizon Pharma USA, Inc.

Terminated

A Long-term Extension of Study RP103-MITO-001 (NCT02023866) to Assess Cysteamine Bitartrate Delayed-release Capsules (RP103) in Children With Inherited Mitochondrial Disease

Mitochondrial Diseases

United States
Horizon Pharma USA, Inc.

Completed

Long-Term Safety Follow-up Study of Cysteamine Bitartrate Delayed-release Capsules (RP103)

Cystinosis

France, United States, Netherlands
Horizon Pharma USA, Inc.

Completed

Safety/Effectiveness Study of Cysteamine Bitartrate Delayed-release Capsules (RP103) in Cysteamine Treatment Naive Patients With Cystinosis

Cystinosis

United States, Brazil
Horizon Pharma USA, Inc.

Completed

Open-Label, Safety and Superior Effectiveness Study of Cysteamine Bitartrate Delayed-Release Capsules (RP103) in Cystinosis

Cystinosis

France, United States, United Kingdom, Belgium, Italy, Netherlands
Horizon Pharma USA, Inc.

Completed

Phase 3 Study of Cysteamine Bitartrate Delayed-release (RP103) Compared to Cystagon® in Patients With Cystinosis

Cystinosis

France, United States, Netherlands
Reviva Pharmaceuticals

Recruiting

Safety and Efficacy of Brilaroxazine (RP5063) in Schizophrenia (RECOVER)

Schizophrenia

United States
Celgene

Completed

Study of Ozanimod (RPC1063) in Relapsing Multiple Sclerosis (MS) (SUNBEAM)

Multiple Sclerosis

United States, Spain, Czechia, Russian Federation, Portugal, Serbia, United Kingdom, New Zealand, Belarus, Bulgaria, Poland, Romania, Estonia, Germany, Sweden, Ukraine, Hungary, Croatia, Georgia, Bosnia and Herzegovina, Latvia, Li... and more
Reviva Pharmaceuticals

Completed

RP5063 in Subjects With Schizophrenia or Schizoaffective Disorder (REFRESH)

Schizoaffective Disorder | Acute Schizophrenia

United States, India, Malaysia, Moldova, Republic of, Philippines

Search clinical trials for: RPC1063

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Hong Kong

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations